[go: up one dir, main page]

NO20054767L - Compositions comprising apomorphine for lung inhalation - Google Patents

Compositions comprising apomorphine for lung inhalation

Info

Publication number
NO20054767L
NO20054767L NO20054767A NO20054767A NO20054767L NO 20054767 L NO20054767 L NO 20054767L NO 20054767 A NO20054767 A NO 20054767A NO 20054767 A NO20054767 A NO 20054767A NO 20054767 L NO20054767 L NO 20054767L
Authority
NO
Norway
Prior art keywords
apomorphine
formulations
compositions
present
sexual dysfunction
Prior art date
Application number
NO20054767A
Other languages
Norwegian (no)
Other versions
NO20054767D0 (en
Inventor
John Nicholas Staniforth
David Morton
Michael Tobyn
Stephen Eason
Quentin Harmer
David Ganderton
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/413,022 external-priority patent/US20040204439A1/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of NO20054767D0 publication Critical patent/NO20054767D0/en
Publication of NO20054767L publication Critical patent/NO20054767L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse angår inhalerbare formuleringer av apomorfin eller farmasøytisk akseptable salter derav eller estere, for anvendelse ved behandling av seksuell dysfunksjon. Foreliggende oppfinnelse angår også metoder for fremstilling av apomorfin-formuleringene, så vel som metoder for behandling av seksuell dysfunksjon ved anvendelse av de nevnte formuleringer og inhalatorer som omfatter de nevnte formuleringer. Foreliggende oppfinnelse angår videre anvendelsen av apomorfin ved fremstilling av et legemiddel for behandling av seksuell dysfunksjon.The present invention relates to inhalable formulations of apomorphine or pharmaceutically acceptable salts thereof or esters, for use in the treatment of sexual dysfunction. The present invention also relates to methods for preparing the apomorphine formulations, as well as methods for treating sexual dysfunction using said formulations and inhalers comprising said formulations. The present invention further relates to the use of apomorphine in the manufacture of a medicament for the treatment of sexual dysfunction.

NO20054767A 2003-04-14 2005-10-17 Compositions comprising apomorphine for lung inhalation NO20054767L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/413,022 US20040204439A1 (en) 2003-04-14 2003-04-14 Composition, device, and method for treating sexual dysfunction via inhalation
US10/621,964 US20040204440A1 (en) 2003-04-14 2003-07-17 Composition, device, and method for treating sexual dysfunction via inhalation
PCT/GB2004/001627 WO2004089374A1 (en) 2003-04-14 2004-04-14 Pharmaceutical compositions comprising apomorphine for pulmonary inhalation

Publications (2)

Publication Number Publication Date
NO20054767D0 NO20054767D0 (en) 2005-10-17
NO20054767L true NO20054767L (en) 2005-12-21

Family

ID=33161980

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054767A NO20054767L (en) 2003-04-14 2005-10-17 Compositions comprising apomorphine for lung inhalation

Country Status (9)

Country Link
US (1) US20060178394A1 (en)
EP (1) EP1613323A1 (en)
JP (1) JP2006522785A (en)
AU (1) AU2004228757A1 (en)
BR (1) BRPI0409380A (en)
CA (1) CA2522231A1 (en)
NO (1) NO20054767L (en)
RU (1) RU2364400C2 (en)
WO (1) WO2004089374A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
RU2440100C2 (en) * 2005-03-28 2012-01-20 Орексо Аб New pharmaceutical compositions effective in treating parkinson's disease
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
MX2011011123A (en) * 2009-04-24 2011-11-04 Schering Corp Agglomerate formulations useful in dry powder inhalers.
TW201304822A (en) * 2010-11-15 2013-02-01 Vectura Ltd Compositions and uses
HK1254812A1 (en) * 2015-06-23 2019-07-26 APIRx Pharmaceuticals, LLC Anti-microbial compositions comprising cannabinoids
US20170071248A1 (en) * 2015-09-16 2017-03-16 Sansa Corporation (Barbados) Inc. System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations
US11224594B2 (en) 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
WO2018007997A1 (en) 2016-07-08 2018-01-11 Trudell Medical International Smart oscillating positive expiratory pressure device
ES2920151T3 (en) 2016-12-09 2022-08-01 Trudell Medical Int smart nebulizer
EP4585247A3 (en) 2018-01-04 2025-07-23 Trudell Medical International Inc. Smart oscillating positive expiratory pressure device
EP4021542B1 (en) 2019-08-27 2025-07-16 Trudell Medical International Inc. Respiratory therapy device comprising a visual feedback array
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US5292520A (en) * 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DK0865789T3 (en) * 1993-03-26 2005-07-18 Franciscus Wilhelmus He Merkus Pharmaceuticals for intranasal administration of dihydroergotamine
DK0978282T3 (en) * 1994-04-22 2006-04-10 Pentech Pharmaceuticals Inc Sublingual preparation containing apomorphine for the diagnosis of functional impotence
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US5699789A (en) * 1996-03-11 1997-12-23 Hendricks; Mark R. Dry powder inhaler
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
ES2236832T3 (en) * 1997-01-16 2005-07-16 Massachusetts Institute Of Technology PREPARATION OF PARTICLES FOR INHALATION.
JP4754067B2 (en) * 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド Composition for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
IT1303788B1 (en) * 1998-11-25 2001-02-23 Chiesi Farma Spa MEDICINAL AEROSOL FORMULATIONS.
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
AU4982300A (en) * 1999-05-06 2000-11-21 Pentech Pharmaceuticals, Inc. Regimen and kit for amelioration of premature ejaculation
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
JP2001072586A (en) * 1999-09-06 2001-03-21 Nikken Chem Co Ltd Powder formulation for inhalation and production method thereof
JP2001151673A (en) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd Method for producing powder formulation for inhalation
BR0005797A (en) * 2000-03-20 2001-10-16 Abbott Lab Methods for the treatment of sexual dysfunction with apomorphine at specified plasma concentration levels
US6506765B2 (en) * 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
US6948494B1 (en) * 2000-05-10 2005-09-27 Innovative Devices, Llc. Medicament container with same side airflow inlet and outlet and method of use
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
EP1341536A4 (en) * 2000-11-15 2007-08-01 Tap Pharmaceutical Prod Inc Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US20020086876A1 (en) * 2000-11-15 2002-07-04 Ruff Dustin D. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
JP2002184831A (en) * 2000-12-11 2002-06-28 Hirata Corp FOUP opener
WO2003026631A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation

Also Published As

Publication number Publication date
CA2522231A1 (en) 2004-10-21
AU2004228757A1 (en) 2004-10-21
RU2005135133A (en) 2006-06-10
WO2004089374A1 (en) 2004-10-21
US20060178394A1 (en) 2006-08-10
JP2006522785A (en) 2006-10-05
BRPI0409380A (en) 2006-04-18
RU2364400C2 (en) 2009-08-20
NO20054767D0 (en) 2005-10-17
EP1613323A1 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
WO2008151235A3 (en) Compositions for delivering medicaments into the lungs, uses thereof
NO20054767L (en) Compositions comprising apomorphine for lung inhalation
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
SG146649A1 (en) Mucoactive agents for treating a pulmonary disease
SE0201669D0 (en) New formulation and use thereof
MEP30108A (en) Formoterol superfine formulation
UY26959A1 (en) NEW INHALATION POWDERS CONTAINING TIOTROPY
EA200702387A1 (en) IMIDAZOCHINOLINES AS LIPIDKINASE INHIBITORS
EA201100305A1 (en) TREATMENT OF RESPIRATORY DISEASES
UA85708C2 (en) Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases
NO20072920L (en) Combination of Methylxanthine Compounds and Steroids to Treat Chronic Respiratory Diseases
WO2010068754A3 (en) Methods and compositions for delivery of medicaments to the lungs
NO20032111L (en) New drug mixtures based on tiotropium salts and on salmeterol salts
NO20063693L (en) Connection and method of use
ATE330589T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING RESVERATROL FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY TRACT
MX2007004495A (en) Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline.
NZ587561A (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
MX2010002498A (en) Methods of treating or preventing respiratory tract infection comprising administering cholecalciferol.
NO20064186L (en) Substituted pyrazoline compositions to reduce blood triglycerides
UA107578C2 (en) COMBINED DIABETES THERAPY
MY153408A (en) Novel methods
NO20063047L (en) Aqueous ciclesonide suspensions for nebulization
EA200600854A1 (en) NEW TIOTROPY SALTS, METHOD OF THEIR PRODUCTION, AND ALSO CONTAINING THEIR MEDICINAL COMPOSITIONS
MXPA06013221A (en) Inhalation powder formulations containing enantiomerically pure beta-agonists.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application